# China NMPA Inspection - Jiangxi Pinxin Pharmaceutical Co., Ltd. - December 25, 2020

Source: https://www.globalkeysolutions.net/records/china_inspection/jiangxi-pinxin-pharmaceutical-co-ltd/ade5e227-6bf9-4c29-8aa3-18f593fc90b3/
Source feed: China

> China NMPA unannounced inspection for Jiangxi Pinxin Pharmaceutical Co., Ltd. published December 25, 2020. The Jiangxi Provincial Drug Administration, operating under the National Medical Products Administration (NMPA) framework, conducted follow-up inspect

---

## Details

- Record Type: CHINA_INSPECTION
- Title: Announcement of the Jiangxi Provincial Drug Administration on the Supervision and Inspection of Cosmetic Manufacturers (Announcement No. 47 of 2020)
- Company Name: Jiangxi Pinxin Pharmaceutical Co., Ltd.
- Publication Date: 2020-12-25
- Product Type: cosmetics
- Summary: The Jiangxi Provincial Drug Administration, operating under the National Medical Products Administration (NMPA) framework, conducted follow-up inspections of six cosmetics manufacturers between November and December 2020. These inspections aimed to ensure companies upheld their primary responsibilities for product quality and safety. Key findings revealed various non-compliance issues across all inspected companies. Jiangxi Chuxin Pharmaceutical Co., Ltd. faced the most severe outcome, with 6 serious and 13 general deficiencies leading to production suspension until confirmed rectification. Jiangxi Chumei Cosmetics Co., Ltd. was cited for 4 serious and 11 general defects, alongside inadequate domestic non-special use cosmetics registration materials, with related issues to be handled according to law. The remaining four companies—Fuzhou Liangfen Cosmetics Co., Ltd., Jiangxi Meilijia Biotechnology Co., Ltd., Ruichang Ruimei Cosmetics Co., Ltd., and Jiangxi Worun Biotechnology Co., Ltd.—were all identified with multiple serious and general or minor deficiencies. For these four companies, the common required action is to rectify the identified deficiencies and submit a rectification report to the Jiangxi Provincial Drug Administration within 30 days. This oversight reflects a concerted effort by Chinese regulatory bodies to enforce stringent quality control within the cosmetics manufacturing sector.

Company: https://www.globalkeysolutions.net/companies/jiangxi-pinxin-pharmaceutical-co-ltd/bdb1ef72-0c91-401f-9c5b-1a9deab9a631/